Hyphens Pharma International Limited (1J5) Fair Value & Analysis
Healthcare · SG · Market cap 108M SGD
Fair value as of: Jul 4, 2026
From 24 valuation models · updated today
Share price +7.7% over the past month.
Price vs Fair Value (12 months)
12‑month range 0.2777 SGD – 0.3735 SGD · fair‑value band 0.3000 SGD – 0.5000 SGD · the 0.3500 SGD price screens below the 0.4000 SGD fair value. As of Jul 4, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Hyphens Pharma International Limited (1J5) currently trades at 0.3500 SGD, while our model-based Fair Value estimate is 0.4000 SGD — implying the stock looks roughly 14.3% undervalued today. We read business quality at 74/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Hyphens Pharma International Limited generated revenue of 177M SGD at a net margin of 3.3%. Revenue declined 15.4% year over year. It earns a return on equity of 8.3%. The stock trades on a trailing P/E of 17.5. Fundamentals as of Jul 4, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.
About the company
Hyphens Pharma International Limited, together with its subsidiaries, operates as a specialty pharmaceutical and consumer healthcare company primarily in Singapore, Vietnam, Malaysia, and internationally. It operates through Pharmaceutical and Medical Aesthetics; Proprietary Brands; and Digital Platform and E-Pharmacy segments. The Pharmaceutical and Medical Aesthetics segment markets and sells a range of pharmaceutical and medical aesthetics products, including the Stérimar nasal sprays, Bausch+Lomb eye drops, Vivomixx, Fenosup Lidose, and Piascledine products in ASEAN countries. This segment focuses on various therapeutic areas, such as dermatology, pediatrics and neonatology, allergy, otorhinolaryngology, orthopedics and rheumatology, radiology, cardiology and interventional cardiology, ophthalmology, gastroenterology, psychiatry, family medicine, and medical aesthetics. Its Proprietary Brands segment develops, markets, and sells dermatological products comprising Ceradan, TDF, …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Hyphens Pharma International Limited reported revenue of 177M SGD in FY2025 versus 126M SGD in FY2021, a compound +8.9%/yr. Reported net income was 5.8M SGD in FY2025, compounding −3.9%/yr from FY2021.
Is 1J5 fairly valued? → Check now
Similar stocks
6 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McKesson Corporation M1CK34 | R$999.49 | R$1,236 | +24% |
| Cencora, Inc C1CO34 | R$707.04 | R$79.88 | -89% |
| Cardinal Health, Inc CAH | $201.74 | $92.07 | -54% |
| Sigma Healthcare Limited SIGGF | $2.35 | $0.6300 | -73% |
| Shanghai Pharmaceuticals Holding 601607 | ¥15.96 | ¥45.15 | +183% |
| Henry Schein, Inc HSIC | $76.30 | $53.31 | -30% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Hyphens Pharma International Limited (1J5) undervalued?
What is the fair value of 1J5?
What is the quality score of 1J5?
What is the revenue of Hyphens Pharma International Limited (1J5)?
What is the net profit margin of 1J5?
Does Hyphens Pharma International Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.